Factors | Progression-free survival | Overall survival | ||||
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||
HR (95% CI) | P value | P value | HR (95% CI) | P value | P value | |
Histologic subtype | ||||||
Squamous cell carcinoma vs adenocarcinoma | 0.28 (0.10–0.81) | 0.01 | 0.25 | 0.33 (0.10–1.07) | 0.05 | 0.54 |
PIK3CA | ||||||
Mutant vs Wild-type | 0.33 (0.10–1.05) | 0.05 | 0.15 | 0.23 (0.05–1.08) | 0.04 | 0.78 |
PTEN | ||||||
Altered vs Wild-type | 3.71e-09 (0–Inf) | 0.05 | 0.41 | 3.64e-09 (0–Inf) | 0.08 | 0.77 |
ERBB3 | ||||||
Mutant vs Wild-type | 34.9 (3.09–394.00) | ˂ 0.001 | 0.01 | 19.8 (2.71–144.00) | ˂ 0.001 | 0.02 |
PI3K/AKT pathway | ||||||
Altered vs Wild-type | 0.33 (0.11–0.94) | 0.03 | 0.09 | 0.25 (0.08–0.84) | 0.02 | 0.97 |
PD-L1 expression | ||||||
Positive vs negative | 0.36 (0.11–1.19) | 0.08 | 0.01 | 0.31 (0.09–1.06) | 0.05 | 0.02 |
TMB | ||||||
≥5 mut/Mb vs<5 mut/Mb | 0.26 (0.09–0.77) | 0.01 | 0.01 | 0.31 (0.09–1.07) | 0.05 | 0.18 |
CI, confidence interval; HR, hazard ratio; mut/Mb, mutations per megabase; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden.